Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021

Marta Grgič Vitek; Irena Klavs; Veronika Učakar; Mojca Serdt; Maja Mrzel; Marjana Vrh; Mario Fafangel

doi:10.2807/1560-7917.ES.2022.27.1.2101110

Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021

Euro Surveill. 2022 Jan;27(1):2101110. doi: 10.2807/1560-7917.ES.2022.27.1.2101110.

Authors

Marta Grgič Vitek¹, Irena Klavs¹, Veronika Učakar¹, Mojca Serdt¹, Maja Mrzel¹, Marjana Vrh¹, Mario Fafangel¹

Affiliation

¹ Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia.

PMID: 34991780
PMCID: PMC8739341
DOI: 10.2807/1560-7917.ES.2022.27.1.2101110

Abstract

We estimated vaccine effectiveness (VE) against severe COVID-19 during October 2021, using Slovenian surveillance data. For people fully vaccinated with any vaccine in age groups 18-49, 50-64, ≥ 65 years, VE was 86% (95% CI: 79-90), 89% (85-91), and 77% (74-81). Among ≥ 65 year-olds fully vaccinated with mRNA vaccines, VE decreased from 93% (95% CI: 88-96) in those vaccinated ≤ 3 months ago to 43% (95% CI: 30-54) in those vaccinated ≥ 6 months ago, suggesting the need for early boosters.

Keywords: COVID-19; Slovenia; mRNA vaccines; severe acute respiratory infection (SARI); surveillance; vaccine effectiveness; viral vector vaccines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
COVID-19*
Hospitalization
Humans
SARS-CoV-2
Slovenia / epidemiology
Vaccine Efficacy
mRNA Vaccines

Substances

mRNA Vaccines